Elanco (2024)

FAQs

Is Elanco owned by Bayer? ›

Leverkusen, August 3, 2020 – Bayer has completed the sale of its Animal Health business unit to U.S. company Elanco Animal Health Incorporated.

announced March 11 that it is now a fully independent company. The completion of Eli Lilly & Co.'s exchange offer finalizes the journey Elanco began in 2017 when its former parent company first announced the exploration of potential strategic alternatives for the 64-year-old animal health company.

Elanco acquires Novartis Animal Health. The combined organization is committed to leading the animal health industry in delivering innovation and customer value.

Pet health is much more than preventative medicine, and at Elanco we are also focused on providing innovative treatments to support pets with chronic diseases such as skin allergies, osteoarthritis and heart disease.

In the 1960s, the Agro-Industrial division was reorganised launching Elanco Products, short for the parent company name, Eli Lilly and Company.

Leverkusen, June 7, 2018 - Bayer successfully completed the acquisition of Monsanto on Thursday. Shares in the U.S. company will no longer be traded on the New York Stock Exchange, with Bayer now the sole owner of Monsanto Company. Monsanto shareholders are being paid 128 U.S. dollars per share.

Eli Lilly and Co. completed its separation from Elanco Animal Health Inc. after completing an exchange offer to divest its 80.2% stake in the animal health business.

Jeffrey Simmons serves as president and chief executive officer of Elanco Animal Health. A global leader with a nearly 70-year track record of growth, Elanco provides comprehensive products and knowledge services to improve animal health, welfare and food animal production across 19 species in almost 100 countries.

Consensus from 10 of the American Pharmaceuticals analysts is that Elanco Animal Health is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$87m in 2025. So, the company is predicted to breakeven just over a year from now.

We are providing engineering services for Elanco Animal Health Corporate Headquarters in Indianapolis, Indiana.

How much did Elanco pay for Bayer? ›

A $7 billion pet healthcare acquisition

Elanco paid $5.2 billion in cash and issued 72.9 million in shares to Bayer. This makes it one of the most expensive deals in the animal healthcare industry's history. Elanco pursued the Bayer merger for two key reasons.

GREENFIELD, Ind. (Inside INdiana Business) — For the first time since becoming an independent company, Greenfield-based Elanco Animal Health (NYSE: ELAN) has been added to the Fortune 1000, a list of the largest U.S. incorporated companies published by Fortune magazine. The company ranks number 768.

Elanco is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole.

At Elanco, we have nearly 10,000 employees across the world. We recognize that the strength of our organization lies in the richness of our people's experiences, backgrounds, and perspectives.

Elanco is departing Hanco*ck County and relocating their headquarters to a new $100 million campus currently being built just west of downtown Indianapolis.

Bayer has owned Alka-Seltzer since 1978. In 1978, Bayer purchased Miles Laboratories and its subsidiaries Miles Canada and Cutter Laboratories, acquiring along with them a variety of product lines including Alka-Seltzer, Flintstones vitamins and One-A-Day vitamins, and Cutter insect repellent.

Elanco closes acquisition of Bayer Animal Health Elanco closes acquisition of Bayer Animal Health. The acquisition strengthens Elanco's Innovation, Portfolio and Productivity strategy. Elanco Animal Health Incorporated has closed the acquisition of Bayer Animal Health. The transaction is valued at $6.89 billion.

Bayer

Bayer Pharma AG / Parent organization

Elanco U.S. Inc., a subsidiary of Eli Lilly and Company, announced this past October an agreement to acquire Boehringer Ingelheim Vetmedica Inc.'s U.S. feline, canine, and rabies vaccines businesses as well as a fully integrated manufacturing and research and development site for $885 million.